AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. MDGL
  4. [Form 4] Madrigal Pharmaceuticals, Inc. Insider Trading Activity

[Form 4] Madrigal Pharmaceuticals, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Madrigal Pharmaceuticals Director Paul A. Friedman received new equity compensation on June 20, 2025, consisting of:

  • 715 restricted stock units (RSUs) granted at $0, vesting at the 2026 annual stockholder meeting
  • 1,290 stock options with strike price of $285.73, fully vesting at the 2026 annual stockholder meeting

Following these transactions, Friedman directly owns 187,164 common shares and indirectly holds 655,540 shares through SQN LLC, where he and his spouse serve as managing members. The indirect holdings include a disclaimer of beneficial ownership except for his pecuniary interest. The equity grants appear to be part of standard director compensation, with vesting tied to continued service through the next annual meeting.

Paul A. Friedman, Direttore di Madrigal Pharmaceuticals, ha ricevuto una nuova compensazione azionaria il 20 giugno 2025, composta da:

  • 715 unit脿 di azioni vincolate (RSU) assegnate al prezzo di $0, con maturazione prevista per l'assemblea annuale degli azionisti del 2026
  • 1.290 opzioni su azioni con prezzo di esercizio di $285,73, che maturano completamente all'assemblea annuale del 2026

Dopo queste operazioni, Friedman possiede direttamente 187.164 azioni ordinarie e detiene indirettamente 655.540 azioni tramite SQN LLC, dove lui e il coniuge ricoprono il ruolo di membri gestori. Le partecipazioni indirette includono una rinuncia alla titolarit脿 effettiva, fatta eccezione per il suo interesse patrimoniale. Le assegnazioni azionarie sembrano far parte della normale compensazione per i direttori, con la maturazione legata alla continuit脿 del servizio fino alla prossima assemblea annuale.

Paul A. Friedman, Director de Madrigal Pharmaceuticals, recibi贸 una nueva compensaci贸n en acciones el 20 de junio de 2025, que consiste en:

  • 715 unidades restringidas de acciones (RSU) otorgadas a $0, con adquisici贸n de derechos en la reuni贸n anual de accionistas de 2026
  • 1,290 opciones sobre acciones con precio de ejercicio de $285.73, que se consolidan completamente en la reuni贸n anual de 2026

Luego de estas transacciones, Friedman posee directamente 187,164 acciones comunes y mantiene indirectamente 655,540 acciones a trav茅s de SQN LLC, donde 茅l y su c贸nyuge act煤an como miembros administradores. Las tenencias indirectas incluyen una renuncia a la propiedad beneficiaria excepto por su inter茅s pecuniario. Las concesiones de acciones parecen formar parte de la compensaci贸n est谩ndar para directores, con la adquisici贸n condicionada a la continuidad del servicio hasta la pr贸xima reuni贸n anual.

Paul A. Friedman电� Madrigal Pharmaceuticals鞚� 鞚挫偓搿滌劀 2025雲� 6鞗� 20鞚检棎 雼れ潓瓿� 臧欖潃 鞁犼窚 欤检嫕 氤挫儊鞚� 氚涭晿鞀惦媹雼�:

  • 715臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)臧� $0鞐� 攵�鞐悩鞐堨溂氅�, 2026雲� 鞐半 欤检＜齑濏殞鞐愳劀 鞕勳爠頌� 旆摑霅╇媹雼�
  • 1,290臧滌潣 欤检嫕 毵れ垬 鞓奠厴鞚� 頄夓偓臧� $285.73搿� 攵�鞐悩鞐堨溂氅�, 2026雲� 鞐半 欤检＜齑濏殞鞐愳劀 鞝勲┐ 旆摑霅╇媹雼�

鞚� 瓯半灅 鞚错泟 Friedman鞚� 歆侅爲鞝侅溂搿� 187,164欤检潣 氤错喌欤�毳� 氤挫湢頃橁碃 鞛堨溂氅�, 氚办毎鞛愳檧 頃粯 甏�毽� 氅る矂搿� 鞛埖鐢 SQN LLC毳� 韱淀暣 655,540欤�毳� 臧勳爲 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 臧勳爲 氤挫湢 欤检嫕鞚� 旮堨爠鞝� 鞚错暣甏�瓿� 鞕胳棎电� 鞁れ鞝� 靻岇湢甓岇潉 攵�鞚疙晿电� 雮挫毄鞚� 韽暔頃╇媹雼�. 鞚� 欤检嫕 氤挫儊鞚� 鞚茧皹鞝侅澑 鞚挫偓 氤挫儊 韺偆歆�鞚� 鞚茧秬搿� 氤挫澊氅�, 旆摑 臁瓣贝鞚� 雼れ潓 鞐半 齑濏殞旯岇鞚� 攴茧 歆�靻嶌棎 鞐半彊霅橃柎 鞛堨姷雼堧嫟.

Paul A. Friedman, directeur de Madrigal Pharmaceuticals, a re莽u une nouvelle r茅mun茅ration en actions le 20 juin 2025, comprenant :

  • 715 unit茅s d'actions restreintes (RSU) attribu茅es 脿 0 $, avec acquisition lors de l'assembl茅e annuelle des actionnaires de 2026
  • 1 290 options d'achat d'actions avec un prix d'exercice de 285,73 $, acquises int茅gralement lors de l'assembl茅e annuelle de 2026

脌 la suite de ces op茅rations, Friedman d茅tient directement 187 164 actions ordinaires et poss猫de indirectement 655 540 actions via SQN LLC, o霉 lui et son conjoint sont membres gestionnaires. Les participations indirectes incluent une renonciation 脿 la propri茅t茅 b茅n茅ficiaire, 脿 l'exception de son int茅r锚t p茅cuniaire. Ces attributions d'actions semblent faire partie d'une r茅mun茅ration standard pour les administrateurs, avec une acquisition conditionn茅e 脿 la poursuite du service jusqu'脿 la prochaine assembl茅e annuelle.

Paul A. Friedman, Direktor von Madrigal Pharmaceuticals, erhielt am 20. Juni 2025 eine neue Aktienverg眉tung, bestehend aus:

  • 715 Restricted Stock Units (RSUs) zum Preis von 0 $, mit Vesting bei der Hauptversammlung 2026
  • 1.290 Aktienoptionen mit einem Aus眉bungspreis von 285,73 $, die vollst盲ndig bei der Hauptversammlung 2026 vesten

Nach diesen Transaktionen besitzt Friedman direkt 187.164 Stammaktien und h盲lt indirekt 655.540 Aktien 眉ber SQN LLC, bei der er und sein Ehepartner als gesch盲ftsf眉hrende Mitglieder t盲tig sind. Die indirekten Beteiligungen beinhalten eine Verzichtserkl盲rung auf wirtschaftliches Eigentum mit Ausnahme seines finanziellen Interesses. Die Aktienzuteilungen scheinen Teil der 眉blichen Verg眉tung f眉r Direktoren zu sein, wobei das Vesting an die Fortsetzung seiner T盲tigkeit bis zur n盲chsten Hauptversammlung gebunden ist.

Positive
  • None.
Negative
  • None.

Paul A. Friedman, Direttore di Madrigal Pharmaceuticals, ha ricevuto una nuova compensazione azionaria il 20 giugno 2025, composta da:

  • 715 unit脿 di azioni vincolate (RSU) assegnate al prezzo di $0, con maturazione prevista per l'assemblea annuale degli azionisti del 2026
  • 1.290 opzioni su azioni con prezzo di esercizio di $285,73, che maturano completamente all'assemblea annuale del 2026

Dopo queste operazioni, Friedman possiede direttamente 187.164 azioni ordinarie e detiene indirettamente 655.540 azioni tramite SQN LLC, dove lui e il coniuge ricoprono il ruolo di membri gestori. Le partecipazioni indirette includono una rinuncia alla titolarit脿 effettiva, fatta eccezione per il suo interesse patrimoniale. Le assegnazioni azionarie sembrano far parte della normale compensazione per i direttori, con la maturazione legata alla continuit脿 del servizio fino alla prossima assemblea annuale.

Paul A. Friedman, Director de Madrigal Pharmaceuticals, recibi贸 una nueva compensaci贸n en acciones el 20 de junio de 2025, que consiste en:

  • 715 unidades restringidas de acciones (RSU) otorgadas a $0, con adquisici贸n de derechos en la reuni贸n anual de accionistas de 2026
  • 1,290 opciones sobre acciones con precio de ejercicio de $285.73, que se consolidan completamente en la reuni贸n anual de 2026

Luego de estas transacciones, Friedman posee directamente 187,164 acciones comunes y mantiene indirectamente 655,540 acciones a trav茅s de SQN LLC, donde 茅l y su c贸nyuge act煤an como miembros administradores. Las tenencias indirectas incluyen una renuncia a la propiedad beneficiaria excepto por su inter茅s pecuniario. Las concesiones de acciones parecen formar parte de la compensaci贸n est谩ndar para directores, con la adquisici贸n condicionada a la continuidad del servicio hasta la pr贸xima reuni贸n anual.

Paul A. Friedman电� Madrigal Pharmaceuticals鞚� 鞚挫偓搿滌劀 2025雲� 6鞗� 20鞚检棎 雼れ潓瓿� 臧欖潃 鞁犼窚 欤检嫕 氤挫儊鞚� 氚涭晿鞀惦媹雼�:

  • 715臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)臧� $0鞐� 攵�鞐悩鞐堨溂氅�, 2026雲� 鞐半 欤检＜齑濏殞鞐愳劀 鞕勳爠頌� 旆摑霅╇媹雼�
  • 1,290臧滌潣 欤检嫕 毵れ垬 鞓奠厴鞚� 頄夓偓臧� $285.73搿� 攵�鞐悩鞐堨溂氅�, 2026雲� 鞐半 欤检＜齑濏殞鞐愳劀 鞝勲┐ 旆摑霅╇媹雼�

鞚� 瓯半灅 鞚错泟 Friedman鞚� 歆侅爲鞝侅溂搿� 187,164欤检潣 氤错喌欤�毳� 氤挫湢頃橁碃 鞛堨溂氅�, 氚办毎鞛愳檧 頃粯 甏�毽� 氅る矂搿� 鞛埖鐢 SQN LLC毳� 韱淀暣 655,540欤�毳� 臧勳爲 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 臧勳爲 氤挫湢 欤检嫕鞚� 旮堨爠鞝� 鞚错暣甏�瓿� 鞕胳棎电� 鞁れ鞝� 靻岇湢甓岇潉 攵�鞚疙晿电� 雮挫毄鞚� 韽暔頃╇媹雼�. 鞚� 欤检嫕 氤挫儊鞚� 鞚茧皹鞝侅澑 鞚挫偓 氤挫儊 韺偆歆�鞚� 鞚茧秬搿� 氤挫澊氅�, 旆摑 臁瓣贝鞚� 雼れ潓 鞐半 齑濏殞旯岇鞚� 攴茧 歆�靻嶌棎 鞐半彊霅橃柎 鞛堨姷雼堧嫟.

Paul A. Friedman, directeur de Madrigal Pharmaceuticals, a re莽u une nouvelle r茅mun茅ration en actions le 20 juin 2025, comprenant :

  • 715 unit茅s d'actions restreintes (RSU) attribu茅es 脿 0 $, avec acquisition lors de l'assembl茅e annuelle des actionnaires de 2026
  • 1 290 options d'achat d'actions avec un prix d'exercice de 285,73 $, acquises int茅gralement lors de l'assembl茅e annuelle de 2026

脌 la suite de ces op茅rations, Friedman d茅tient directement 187 164 actions ordinaires et poss猫de indirectement 655 540 actions via SQN LLC, o霉 lui et son conjoint sont membres gestionnaires. Les participations indirectes incluent une renonciation 脿 la propri茅t茅 b茅n茅ficiaire, 脿 l'exception de son int茅r锚t p茅cuniaire. Ces attributions d'actions semblent faire partie d'une r茅mun茅ration standard pour les administrateurs, avec une acquisition conditionn茅e 脿 la poursuite du service jusqu'脿 la prochaine assembl茅e annuelle.

Paul A. Friedman, Direktor von Madrigal Pharmaceuticals, erhielt am 20. Juni 2025 eine neue Aktienverg眉tung, bestehend aus:

  • 715 Restricted Stock Units (RSUs) zum Preis von 0 $, mit Vesting bei der Hauptversammlung 2026
  • 1.290 Aktienoptionen mit einem Aus眉bungspreis von 285,73 $, die vollst盲ndig bei der Hauptversammlung 2026 vesten

Nach diesen Transaktionen besitzt Friedman direkt 187.164 Stammaktien und h盲lt indirekt 655.540 Aktien 眉ber SQN LLC, bei der er und sein Ehepartner als gesch盲ftsf眉hrende Mitglieder t盲tig sind. Die indirekten Beteiligungen beinhalten eine Verzichtserkl盲rung auf wirtschaftliches Eigentum mit Ausnahme seines finanziellen Interesses. Die Aktienzuteilungen scheinen Teil der 眉blichen Verg眉tung f眉r Direktoren zu sein, wobei das Vesting an die Fortsetzung seiner T盲tigkeit bis zur n盲chsten Hauptversammlung gebunden ist.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
FRIEDMAN PAUL A
(Last) (First) (Middle)
C/O MADRIGAL PHARMACEUTICALS, INC.
200 BARR HARBOR DRIVE, SUITE 400
(Street)
WEST CONSHOHOCKEN PA 19428
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MADRIGAL PHARMACEUTICALS, INC. [ MDGL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 A(1) 715 A $0 187,164 D
Common Stock 655,540 I By SQN LLC(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $285.73 06/20/2025 A 1,290 (3) 06/20/2035 Common Stock 1,290 $0 1,290 D
Explanation of Responses:
1. Represents a grant of restricted stock units, which vest on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided the Reporting Person continues in service with the Issuer on such date.
2. The Reporting Person and his spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
3. The option vests as to 100% of underlying shares on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided that the Reporting Person continues to serve as a director of the Issuer until such date.
Remarks:
/s/ Mardi Dier, as Attorney-in-Fact 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many shares of MDGL stock did Paul Friedman acquire on June 20, 2025?

On June 20, 2025, Paul Friedman acquired 715 shares of MDGL common stock in the form of restricted stock units (RSUs) and 1,290 stock options with an exercise price of $285.73.

What is the vesting schedule for MDGL director Paul Friedman's new stock grants?

Both the restricted stock units and stock options will vest 100% on the date of Madrigal Pharmaceuticals' annual meeting of stockholders to be held in 2026, contingent on Friedman continuing to serve as a director until that date.

How many MDGL shares does Paul Friedman own directly after the June 2025 grants?

Following the reported transactions, Paul Friedman directly owns 187,164 shares of MDGL common stock, plus 1,290 unvested stock options.

What is Paul Friedman's indirect ownership of MDGL stock through SQN LLC?

Paul Friedman has indirect beneficial ownership of 655,540 shares of MDGL through SQN LLC, where he and his spouse serve as managing members. However, he disclaims beneficial ownership except for his pecuniary interest.

What is the exercise price and expiration date of MDGL stock options granted to Paul Friedman?

The stock options were granted with an exercise price of $285.73 per share and will expire on June 20, 2035, ten years from the grant date.
Stock MDGL logo
Madrigal Pharmac

NASDAQ:MDGL

MDGL Rankings

#1482 Ranked by Market Cap
N/A Ranked by Dividends

MDGL Latest News

Jul 30, 2025
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
Jul 25, 2025
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and聽Host Webcast on August 5, 2025
Jul 22, 2025
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH
Jul 16, 2025
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Jul 16, 2025
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra鈩� (Resmetirom)

MDGL Latest SEC Filings

Jul 30, 2025
[8-K] Madrigal Pharmaceuticals, Inc. Reports Material Event
Jul 22, 2025
[Form 4] Madrigal Pharmaceuticals, Inc. Insider Trading Activity
Jul 22, 2025
[Form 4] Madrigal Pharmaceuticals, Inc. Insider Trading Activity
Jul 22, 2025
[8-K] Madrigal Pharmaceuticals, Inc. Reports Material Event
Jul 18, 2025
[144] Madrigal Pharmaceuticals, Inc. SEC Filing

MDGL Stock Data

6.44B
20.43M
8.74%
105.1%
17%
Biotechnology
Pharmaceutical Preparations
United States
WEST CONSHOHOCKEN